31 Jan 2025
The number of shares and votes in Xbrane has changed as a result of 2,706,898 shares being issued during January through the exercise of warrants in December 2024.
09 Jan 2025
Xbrane Biopharma AB (publ) (“Xbrane” or “the company) appoints Jane Benyamin as acting Chief Financial Officer.
31 Dec 2024
XBRANE RE-SUBMITS BLA FOR RANIBIZUMAB BIOSIMILAR CANDIDATE TO FDA
18 Dec 2024
Xbrane announces outcome of exercise of warrants of series TO1
02 Dec 2024
XBRANE BIOPHARMA’S PRINCIPAL OWNER SYSTEMATIC GROUP PROVIDES A SHORT-TERM LOAN OF SEK 20 M TO THE COMPANY
26 Nov 2024
Xbrane AB (publ) today announces that the company’s CFO, Anette Lindqvist, has announced her intention to retire and will leave her position during the spring of 2025.
21 Nov 2024
XBRANE BIOPHARMA ANNOUNCES NOMINATION COMMITTEE CHANGES
19 Nov 2024
Xbrane and Intas enter into a Global Licensing agreement to jointly develop Nivolumab biosimilar referencing Opdivo®
31 Oct 2024
XBRANE BIOPHARMA PRESENTS NOMINATION COMMITTEE